



0420 #2  
03CO

PATENT  
459-615P

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant: BJORN, Sara P. et al      Conf.: unassigned  
Appl. No.: 09/887,784      Group: unassigned  
Filed: June 19, 2001      Examiner: UNASSIGNED  
For: NOVEL FLUORESCENT PROTEINS

LETTER

Assistant Commissioner for Patents  
Washington, DC 20231

August 3, 2001

Sir:

Under the provisions of 35 U.S.C. § 119 and 37 C.F.R. § 1.55(a), the applicant(s) hereby claim(s) the right of priority based on the following application(s):

<u>Country</u>	<u>Application No.</u>	<u>Filed</u>
DENMARK	PA 2001 00739	May 10, 2001
DENMARK	PA 2000 00953	June 19, 2000

A certified copy of the above-noted application(s) is(are) attached hereto.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fee required under 37 C.F.R. §§ 1.16 or 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By Leonard R. Svensson #46,183 for  
Leonard R. Svensson, #301330

LRS/KR/clh  
459-615P

P.O. Box 747  
Falls Church, VA 22040-0747  
(703) 205-8000

Attachment



# Kongeriget Danmark

Patent application No.: PA 2001 00739

Date of filing: 10 May 2001

Applicant: Biolmage A/S  
Mørkhøj Bygade 28  
DK-2860 Søborg

This is to certify the correctness of the following information:


The attached photocopy is a true copy of the following document:

- The specification, claims and figures as filed with the application on the filing date indicated above.



Patent- og  
Varemærkestyrelsen  
Erhvervsministeriet

Taastrup 29 June 2001

  
Karin Schlichting  
Hvad til

Patent- og  
Varemærkestyrelsen

10 MAJ 2001

Modtaget

## NOVEL FLUORESCENT PROTEINS

### Field of invention

The present invention relates to novel variants of the fluorescent protein GFP having improved fluorescence properties.

### 5 Background

The discovery that Green Fluorescent Protein (GFP) from the jellyfish *A. victoria* retains its fluorescent properties when expressed in heterologous cells has provided biological research with a new, unique and powerful tool (Chalfie et al (1994). Science 263:802; Prasher (1995) Trends in Genetics 11:320; WO 95/07463). A very important aspect of  
10 using recombinant, fluorescent proteins in studying cellular functions is the non-invasive nature of the assay. This allows detection of cellular events in intact, living cells.

The excitation spectrum of the green fluorescent protein from *Aequorea victoria* shows two peaks: A major peak at 396nm, which is in the potentially cell damaging UV range, and a lesser peak at 475nm, which is in an excitation range that is much less harmful to  
15 cells.

To improve the wild type GFP, a range of mutations have been described. Heim (GFP (Heim et al. (1994). Proc.Natl.Acad.Sci. 91:12501) described the discovery of a blue fluorescent variant which has greatly increased the potential applications of using fluorescent recombinant probes to monitor cellular events or functions, since the availability of probes  
20 having different excitation and emission spectra permits simultaneous monitoring of more than one process. However, the blue fluorescing variant described by Heim et al, Y66H-GFP, suffers from certain limitations: The blue fluorescence is weak (emission maximum at 448nm), thus making detection difficult, and necessitating prolonged excitation of cells expressing Y66H-GFP. Moreover, the prolonged period of excitation is damaging to cells  
25 especially because the excitation wavelength is in the UV range, 360nm - 390nm.

Heim et al.(1995), Nature, Vol. 373, p. 663-4, discloses a Ser65Thr mutation of GFP (S65T) having longer wavelengths of excitation and emission, 490nm and 510nm, re-

spectively, than the wild-type GFP and wherein the fluorophore formation proceeded about fourfold more rapidly than in the wild-type GFP.

- Ehrig et al. (1995) FEBS Letters 367, 163-166, discloses a E222G mutant of the *Aequorea* green fluorescent protein. This mutation has an excitation maximum of 481nm and an  
5 emission maximum at 506nm.

- Expression of GFP or its fluorescent variants in living cells provides a valuable tool for studying cellular events and it is well known that many cells, including mammalian cells, are incubated at approximately 37°C in order to secure optimal and/or physiologically relevant growth. Cell lines originating from different organisms or tissues may have differ-  
10 ent relevant temperatures ranging from about 35°C for fibroblasts to about 38°C - 39°C for mouse  $\beta$ -cells. Experience has shown, however, that the fluorescent signal from cells expressing GFP is weak or absent when said cells are incubated at temperatures above room temperature, cf. Webb, C.D. et al., Journal of Bacteriology, Oct. 1995, p. 5906-5911. Ogawa H. et al., Proc. Natl. Acad. Sci. USA, Vol. 92, pp. 11899-11903, December 1995,  
15 and Lim et al. J. Biochem. 118, 13-17 (1995). The improved fluorescent variant S65T described by Heim et al. (1995) supra also displays very low fluorescence when incubated under normal culture conditions (37°C), cf. Kaether and Gerdes FEBS Letters 369 (1995) pp. 267-271. Many experiments involving the study of cell metabolism are dependent on the possibility of incubating the cells at physiologically relevant temperatures, i.e. tem-  
20 peratures at about 37°C.

Thastrup et al. (1997) EP 0 851 874 describes fluorescent proteins that exhibit high fluorescence in cells expressing them when said cells are incubated at a temperature of 30°C or above. This is obtained with the amino acid in position 1 preceding the chromophore has been mutated. Examples of such mutations are F64L, F64I, F64V F64A and F64G.

- 25 Various authors have experimented with combinations of mutations. One such combination is the F64L, S65T GFP (EGFP). EGFP exhibits high fluorescence when expressed at 30°C or above and has an excitation maximum at 488nm.

## SUMMARY OF THE INVENTION

The present invention provides novel fluorescent proteins, such as F64L-E222G-GFP that result in a cellular fluorescence far exceeding the cellular fluorescence when expressed at 37°C and when excited at about 500nm compared to the parent proteins, i.e. GFP, the blue variant Y66H-GFP the S65T-GFP variant, and F64L-GFP. This greatly improves the usefulness of fluorescent proteins in studying cellular functions in living cells.

It is shown that GFP mutated at the 64 position from F to L (F64L) and at the 222 position from E to G (E222G) has remarkable properties. It is first shown that the F64L,E222G-GFP has an entirely different spectrum than F64L,S65T-GFP (example 2). In contrast, there is no substantial difference between folding characteristics (measured as the time when fluorescence is observed between the two GFPs, example 3). Likewise, there was no difference between the pH sensitivity of the two GFPs (example 4), nor between the "greenness" of the two GFPs expressed with jellyfish backbone or mammalian backbone (example 7).

## DETAILED DESCRIPTION OF THE INVENTION

One aspect of the present invention relates to a fluorescent protein derived from Green Fluorescent Protein (GFP) or any functional GFP analogue, wherein the amino acid in position 1 preceding the chromophore has been mutated and wherein the Glutamic acid in position 222 has been mutated to Glycine said mutated GFP has an excitation maximum at a higher wavelength compared to F64L-GFP and the fluorescence is increased when the mutated GFP is expressed in cells incubated at a temperature of 30°C or above compared to wild-type GFP.

The excitation and emission characteristics of the F64L,E222G-GFP differ significantly from wild-type GFP and EGFP. Existing fluorescent proteins have demonstrated utility for research applications such as quantitative fluorescence microscopy (Patterson, G.H., *et al* (1997). *Biophysical J.* **73**:2782-2790; Piston, D.W., *et al* (1999) *Meth. Cell Biol.* **58**:31-48). It is now clear, however, that the optimal fluorescent protein characteristics for high-throughput screening (HTS) applications in drug discovery differ somewhat from those for research applications (Kain, S. R. (1999) *Drug Discovery Today* **4**:304-312). For example, factors such as optimal and signal/noise are more important for HTS applications in drug discovery than are absolute brightness of probes such as fluorescent proteins. The

F64L,E222G-GFP described in this patent application has an excitation maximum of 470 nm and an emission maximum of 505 nm (see Figure 1), compared to the respective excitation and emission maxima of 490 nm and 510 nm for EGFP. This results in a Stokes shift of 35 nm for F64L,E222G-GFP, as compared to 20 nm for EGFP. The forms of the F64L,E222G-GFP excitation and emission peaks and the full width at half maximal intensity (FWHM) remain similar to those of EGFP. This results in a significant increase in the excitation-emission band separation for F64L,E222G-GFP relative to EGFP with several implications for the use of F64L,E222G-GFP in high-throughput screening. Some of these are listed below:

1. The increased Stokes shift of F64L,E222G-GFP results in increased spectral resolution of its excitation and emission peaks. This enables more complete band separation using a conventional dichroic beam-splitter, and decreased background signal for assays incorporating F64L,E222G-GFP relative to assays based on EGFP.
2. F64L,E222G-GFP fluorescence can be excited by conventional light sources using narrow band filters, or commercially available laser producing lines at 472 nm. In either case, the greater Stokes shift of F64L,E222G-GFP results in lower cross-talk from excitation light to the toe of the emission spectrum.
3. The excitation maximum of F64L,E222G-GFP falls midway between those of the cyan fluorescent protein variant (ECFP, excitation max ~433 nm) and the yellow fluorescent protein variant (EYFP, excitation max ~513 nm). Because of this, it will allow for cleaner band separation when used together with those probes, and it is optimized for assay applications in which several GFP-labeled components will be multiplexed.

Many sources of GFPs exist. Examples are GFP derived from *Aequorea victoria* and GFP derived from *Renilla reniformis*. As described in the examples and in list 2, the chromophore in *Aequorea victoria* is in position 65-67 of the predicted primary amino acid sequence of GFP. Thus, in a preferred embodiment the GFP is derived from *Aequorea victoria*

It is preferred that the mutation at F64 is a mutation to an aliphatic amino acid. Examples are F64L, F64I, F64V, F64A, and F64G, wherein the F64L substitution being most preferred. However other mutations, e.g. deletions, insertions, or post-translational modifications immediately preceding the chromophore are also included in the invention, provided that they

result in improved fluorescence properties of the various fluorescent proteins. It should be noted that extensive deletions may result in loss of the fluorescent properties of GFP.

The E222G, E222A, E222V, E222L, E222I, E222F, E222S, E222T, E222N, E222Q substitutions are preferred, the E222G substitution being most preferred.

- 5 A preferred sequence of the gene encoding GFP derived from *Aequorea victoria* is disclosed in list 2 herein. List 1 shows the nucleotide sequence of F64L-GFP. Besides, the novel fluorescent proteins may also be derived from other fluorescent proteins as mentioned above.

Herein the abbreviations used for the amino acids are those stated in J. Biol. Chem. 243  
10 (1968), 3558.

One aspect of the invention relates to a nucleotide sequence coding for the Fluorescent protein F64L-E222G-GFP. An example of such F64L-E222G-GFP is shown in list 2. In a preferred aspect the nucleotide sequence is in the form of a DNA sequence.

- 15 The DNA construct of the invention encoding the novel fluorescent proteins may be prepared synthetically by established standard methods, e.g. the phosphoamidite method described by Beaucage and Caruthers, Tetrahedron Letters 22 (1981), 1859 - 1869, or the method described by Matthes et al., EMBO Journal 3 (1984), 801 - 805. According to the phosphoamidite method, oligonucleotides are synthesized, e.g. in an automatic DNA synthesizer, purified, annealed, ligated and cloned in suitable vectors.

- 20 The DNA construct may also be prepared by polymerase chain reaction (PCR) using specific primers, for instance as described in US 4,683,202 or Saiki et al., Science 239 (1988), 487 - 491. A more recent review of PCR methods may be found in PCR Protocols, 1990, Academic Press, San Diego, California, USA.

- 25 The DNA construct of the invention may be inserted into a recombinant vector which may be any vector which may conveniently be subjected to recombinant DNA procedures. The choice of vector will often depend on the host cell into which it is to be introduced. Thus, the vector may be an autonomously replicating vector, i.e. a vector which exists as an extrachromosomal entity, the replication of which is independent of chromosomal replication, e.g. a plasmid. Alternatively, the vector may be one which, when introduced into a host

cell, is integrated into the host cell genome and replicated together with the chromosome(s) into which it has been integrated.

The vector is preferably an expression vector in which the DNA sequence encoding the fluorescent protein of the invention is operably linked to additional segments required for transcription of the DNA. In general, the expression vector is derived from plasmid or viral DNA, or may contain elements of both. The term, "operably linked" indicates that the segments are arranged so that they function in concert for their intended purposes, e.g. transcription initiates in a promoter and proceeds through the DNA sequence coding for the fluorescent protein of the invention.

- 10 The promoter may be any DNA sequence which shows transcriptional activity in the host cell of choice and may be derived from genes encoding proteins either homologous or heterologous to the host cell, including native *Aequorea* GFP genes.

Examples of suitable promoters for directing the transcription of the DNA sequence encoding the fluorescent protein of the invention in mammalian cells are the SV40 promoter (Subramani et al., Mol. Cell Biol. 1 (1981), 854 -864), the MT-1 (metallothionein gene) promoter (Palmiter et al., Science 222 (1983), 809 - 814) or the adenovirus 2 major late promoter.

An example of a suitable promoter for use in insect cells is the polyhedrin promoter (US 4,745,051; Vasudevan et al., FEBS Lett. 311, (1992) 7 - 11), the P10 promoter (J.M. Vlak et al., J. Gen. Virology 69, 1988, pp. 765-776), the *Autographa californica* polyhedrosis virus basic protein promoter (EP 397 485), the baculovirus immediate early gene 1 promoter (US 5,155,037; US 5,162,222), or the baculovirus 39K delayed-early gene promoter (US 5,155,037; US 5,162,222).

Examples of suitable promoters for use in yeast host cells include promoters from yeast glycolytic genes (Hitzeman et al., J. Biol. Chem. 255 (1980), 12073 - 12080; Alber and Kawasaki, J. Mol. Appl. Gen. 1 (1982), 419 - 434) or alcohol dehydrogenase genes (Young et al., in Genetic Engineering of Microorganisms for Chemicals (Hollaender et al, eds.), Plenum Press, New York, 1982), or the TPI1 (US 4,599,311) or ADH2-4c (Russell et al., Nature 304 (1983), 652 - 654) promoters.



Examples of suitable promoters for use in filamentous fungus host cells are, for instance, the ADH3 promoter (McKnight et al., The EMBO J. 4 (1985), 2093 - 2099) or the tpiA promoter. Examples of other useful promoters are those derived from the gene encoding *A. oryzae* TAKA amylase, *Rhizomucor miehei* aspartic proteinase, *A. niger* neutral  $\alpha$ -  
 5 amylase, *A. niger* acid stable  $\alpha$ -amylase, *A. niger* or *A. awamori* glucoamylase (gluA), *Rhizomucor miehei* lipase, *A. oryzae* alkaline protease, *A. oryzae* triose phosphate isomerase or *A. nidulans* acetamidase. Preferred are the TAKA-amylase and gluA promoters.

Examples of suitable promoters for use in bacterial host cells include the promoter of the  
 10 *Bacillus stearothermophilus* maltogenic amylase gene, the *Bacillus licheniformis* alpha-amylase gene, the *Bacillus amyloliquefaciens* BAN amylase gene, the *Bacillus subtilis* alkaline protease gene, or the *Bacillus pumilus* xylosidase gene, or by the phage Lambda  $P_R$  or  $P_L$  promoters or the *E. coli* lac, trp or tac promoters.

The DNA sequence encoding the novel fluorescent proteins of the invention may also, if  
 15 necessary, be operably connected to a suitable terminator, such as the human growth hormone terminator (Palmiter et al., op. cit.) or (for fungal hosts) the TPI1 (Alber and Kawasaki, op. cit.) or ADH3 (McKnight et al., op. cit.) terminators. The vector may further comprise elements such as polyadenylation signals (e.g. from SV40 or the adenovirus 5 Elb region), transcriptional enhancer sequences (e.g. the SV40 enhancer) and translation  
 20 enhancer sequences (e.g. the ones encoding adenovirus VA RNAs).

The recombinant vector may further comprise a DNA sequence enabling the vector to replicate in the host cell in question. An example of such a sequence (when the host cell is a mammalian cell) is the SV40 origin of replication.

When the host cell is a yeast cell, suitable sequences enabling the vector to replicate are  
 25 the yeast plasmid  $2\mu$  replication genes REP 1-3 and origin of replication.

The vector may also comprise a selectable marker, e.g. a gene the product of which complements a defect in the host cell, such as the gene coding for dihydrofolate reductase (DHFR) or the *Schizosaccharomyces pombe* TPI gene (described by P.R. Russell, Gene 40, 1985, pp. 125-130), or one which confers resistance to a drug, e.g. ampicillin, kanamycin, tetracyclin, chloramphenicol, neomycin or hygromycin. For filamentous fungi, selectable markers include amdS, pyrG, argB, niaD, sC.  
 30

The procedures used to ligate the DNA sequences coding for the fluorescent protein of the invention, the promoter and optionally the terminator and/or secretory signal sequence, respectively, and to insert them into suitable vectors containing the information necessary for replication, are well known to persons skilled in the art (cf., for instance, 5 Sambrook et al., op.cit.).

The host cell into which the DNA construct or the recombinant vector of the invention is introduced may be any cell which is capable of expressing the present DNA construct and includes bacteria, yeast, fungi and higher eukaryotic cells.

Examples of bacterial host cells which, on cultivation, are capable of expressing the DNA 10 construct of the invention are grampositive bacteria, e.g. strains of *Bacillus*, such as *B. subtilis*, *B. licheniformis*, *B. lentus*, *B. brevis*, *B. stearothermophilus*, *B. alkalophilus*, *B. amyloliquefaciens*, *B. coagulans*, *B. circulans*, *B. lautus*, *B. megatherium* or *B. thuringiensis*, or strains of *Streptomyces*, such as *S. lividans* or *S. murinus*, or gramnegative bacteria such as *Echerichia coli*. The transformation of the bacteria may be effected by proto- 15 plast transformation or by using competent cells in a manner known per se (cf. Sambrook et al., supra).

Examples of suitable mammalian cell lines are the HEK293 and the HeLa cell lines, primary cells, and the COS (e.g. ATCC CRL 1650), BHK (e.g. ATCC CRL 1632, ATCC CCL 10), CHL (e.g. ATCC CCL39) or CHO (e.g. ATCC CCL 61) cell lines. Methods of trans- 20 fecting mammalian cells and expressing DNA sequences introduced in the cells are described in e.g. Kaufman and Sharp, J. Mol. Biol. **159**(1982), 601 - 621; Southern and Berg, J. Mol. Appl. Genet. **1**(1982), 327 - 341; Loyter et al., Proc.Natl. Acad. Sci. USA **79**(1982), 422 - 426; Wigler et al., Cell **14**(1978), 725; Corsaro and Pearson, Somatic Cell Genetics **7**(1981), 603, Graham and van der Eb, Virology **52**(1973), 456; and Neumann 25 et al., EMBO J. **1**(1982), 841 - 845.

Examples of suitable yeast cells include cells of *Saccharomyces* spp. or *Schizosaccharomyces* spp., in particular strains of *Saccharomyces cerevisiae* or *Saccharomyces kluyveri*. Methods for transforming yeast cells with heterologous DNA and producing heterologous polypeptides therefrom are described, e.g. in US 4,599,311, US 4,931,373, US 30 4,870,008, 5,037,743, and US 4,845,075, all of which are hereby incorporated by reference. Transformed cells are selected by a phenotype determined by a selectable marker, commonly drug resistance or the ability to grow in the absence of a particular nutrient, e.g.

leucine. A preferred vector for use in yeast is the POT1 vector disclosed in US 4,931,373. The DNA sequence encoding the fluorescent protein of the invention may be preceded by a signal sequence and optionally a leader sequence, e.g. as described above. Further examples of suitable yeast cells are strains of *Kluyveromyces*, such as *K. lactis*, *Hansenula*, e.g. *H. polymorpha*, or *Pichia*, e.g. *P. pastoris* (cf. Gleeson et al., *J. Gen. Microbiol.* 132, 1986, pp. 3459-3465; US 4,882,279).

Examples of other fungal cells are cells of filamentous fungi, e.g. *Aspergillus* spp., *Neurospora* spp., *Fusarium* spp. or *Trichoderma* spp., in particular strains of *A. oryzae*, *A. nidulans* or *A. niger*. The use of *Aspergillus* spp. for the expression of proteins is described in, e.g., EP 272 277, EP 230 023, EP 184 438.

When a filamentous fungus is used as the host cell, it may be transformed with the DNA construct of the invention, conveniently by integrating the DNA construct in the host chromosome to obtain a recombinant host cell. This integration is generally considered to be an advantage as the DNA sequence is more likely to be stably maintained in the cell. Integration of the DNA constructs into the host chromosome may be performed according to conventional methods, e.g. by homologous or heterologous recombination.

Transformation of insect cells and production of heterologous polypeptides therein may be performed as described in US 4,745,051; US 4,879,236; US 5,155,037; 5,162,222; EP 397,485) all of which are incorporated herein by reference. The insect cell line used as the host may suitably be a *Lepidoptera* cell line, such as *Spodoptera frugiperda* cells or *Trichoplusia ni* cells (cf. US 5,077,214). Culture conditions may suitably be as described in, for instance, WO 89/01029 or WO 89/01028, or any of the aforementioned references.

One aspect of the invention relates to a host transformed with a DNA construct according to any of the preceding claims. The transformed or transfected host cell described above is then cultured in a suitable nutrient medium under conditions permitting the expression of the present DNA construct after which the cells may be used in the screening method of the invention. Alternatively, the cells may be disrupted after which cell extracts and/or supernatants may be analysed for fluorescence.

The medium used to culture the cells may be any conventional medium suitable for growing the host cells, such as minimal or complex media containing appropriate supple-

ments. Suitable media are available from commercial suppliers or may be prepared according to published recipes (e.g. in catalogues of the American Type Culture Collection).

In the method of the invention, the fluorescence of cells transformed or transfected with the DNA construct of the invention may suitably be measured in a spectrometer or a fluorescence microscope where the spectral properties of the cells in liquid culture may be determined as scans of light excitation and emission.

One aspect of the invention relates to a fusion compound consisting of a fluorescent protein (F64L-E222G-GFP), wherein the (F64L-E222G-GFP) is linked to a polypeptide. Examples of such polypeptide is kinase, preferably the catalytic subunit of protein kinase A, or protein kinase C, or Erk1, or a cytoskeletal element.

The invention further relates to a process for preparing a polypeptide, comprising cultivating a host according to any of the preceding aspects and obtaining therefrom the polypeptide expressed by said nucleotide sequence.

The various aspects of the invention have a plethora of uses. Some of these are described below:

Use of F64L-E222G-GFP in an *in vitro* assay for measuring protein kinase activity, or dephosphorylation activity, or for measuring protein redistribution.

Use of F64L-E222G-GFP as a protein tag in living and fixed cells. Due to the strong fluorescence the novel proteins are suitable tags for proteins present at low concentrations. Since no substrate is needed and visualisation of the cells does not damage the cells dynamic analysis can be performed.

Use as an organelle tag. More than one organelle can be tagged and visualised simultaneously in living cells, e.g. the endoplasmic reticulum and the cytoskeleton.

Use as a secretion marker. By fusion of F64L-E222G-GFP to a signal peptide or a peptide to be secreted, secretion may be followed on-line in living cells. A precondition for that is that the maturation of a detectable number of novel fluorescent protein molecules occurs faster than the secretion.

Use as genetic reporter or protein tag in transgenic animals. Due to the strong fluorescence of the novel proteins, they are suitable as tags for proteins and gene expression, since the signal to noise ratio is significantly improved over the prior art proteins, such as wild-type GFP.

- 5 Use as a cell or organelle integrity marker. By co-expressing two of the novel proteins, the one targeted to an organelle and the other expressed in the cytosol, it is possible to calculate the relative leakage of the cytosolic protein and use that as a measure of cell integrity.

- Use as a marker for changes in cell morphology. Expression of the novel proteins in cells  
10 allows easy detection of changes in cell morphology, e.g. blebbing, caused by cytotoxic agents or apoptosis. Such morphological changes are difficult to visualize in intact cells without the use of fluorescent probes.

- Use as a transfection marker, and as a marker to be used in combination with FACS sorting. Due to the increased brightness of the novel proteins the quality of cell detection  
15 and sorting can be significantly improved.

- Use as real-time probe working at near physiological concentrations. Since F64L-E222G-GFP is significantly brighter than wild type GFP and F64L-GFP when expressed in cells at about 37°C and excited with light at about 490 nm, the concentration needed for visualization can be lowered. Target sites for enzymes engineered into the novel proteins, e.g.  
20 F64L-E222G-GFP, can therefore be present in the cell at low concentrations in living cells. This is important for two reasons: 1) The probe must interfere as little as possible with the intracellular process being studied; 2) the translational and transcriptional apparatus should be stressed minimally.

- The novel proteins can be used as reporters to monitor live/dead biomass of organisms,  
25 such as fungi. By constitutive expression of F64L-E222G-GFP in fungi the viable biomass will light up.

Transposon vector mutagenesis can be performed using the novel proteins as markers in transcriptional and translational fusions.

Transposons to be used in microorganisms encoding the novel proteins. The transposons may be constructed for translational and transcriptional fusions. To be used for screening for promoters.

Transposon vectors encoding the novel proteins, such as F64L-E222G-GFP, can be used  
5 for tagging plasmids and chromosomes.

Use as a reporter for bacterial detection by introducing the novel proteins into the genome of bacteriophages.

By engineering the novel proteins, e.g. F64L-E222G-GFP, into the genome of a phage a diagnostic tool can be designed. F64L-E222G-GFP will be expressed only upon transfection  
10 of the genome into a living host. The host specificity is defined by the bacteriophage.

The invention is further illustrated in the following examples with reference to the appended sequence lists.

## Sequence lists

### *List 1: Nucleic acid and amino acid sequence of F64L-GFP*

```

15 1/1                                     31/11
    atg gtg agc aag ggc gag gag ctg ttc acc ggg gtg gtg ccc atc ctg gtc gag ctg gac
    M  V  S  K  G  E  E  L  F  T  G  V  V  P  I  L  V  E  L  D
    61/21                                     91/31
    ggc gac gta aac ggc cac aag ttc agc gtg tcc ggc gag ggc gag ggc gat gcc acc tac
20 G  D  V  N  G  H  K  F  S  V  S  G  E  G  E  G  D  A  T  Y
    121/41                                    151/51
    ggc aag ctg acc ctg aag ttc atc tgc acc acc ggc aag ctg ccc gtg ccc tgg ccc aca
    G  K  L  T  L  K  F  I  C  T  T  G  K  L  P  V  P  W  P  T
    181/61                                    211/71
25 cta gtg acc acc ctg tct tac ggc gtg cag tgc ttc agc cgc tac ccc gac cac atg aag
    L  V  T  T  L  S  Y  G  V  Q  C  F  S  R  Y  P  D  H  M  K
    241/81                                    271/91
    cag cac gac ttc ttc aag tcc gcc atg ccc gaa ggc tac gtc cag gag cgc acc atc ttc
    Q  H  D  F  F  K  S  A  M  P  E  G  Y  V  Q  E  R  T  I  F
30 301/101                                   331/111
    ttc aag gac gac ggc aac tac aag acc cgc gcc gag gtg aag ttc gag ggc gac acc ctg
    F  K  D  D  G  N  Y  K  T  R  A  E  V  K  F  E  G  D  T  L
  
```

361/121 391/131  
 gtg aac cgc atc gag ctg aag ggc atc gac ttc aag gag gac ggc aac atc ctg ggg cac  
 V N R I E L K G I D F K E D G N I L G H  
 421/141 451/151  
 5 aag ctg gag tac aac tac aac agc cac aac gtc tat atc atg gcc gac aag cag aag aac  
 K L E Y N Y N S H N V Y I M A D K Q K N  
 481/161 511/171  
 ggc atc aag gtg aac ttc aag atc cgc cac aac atc gag gac ggc agc gtg cag ctc gcc  
 G I K V N F K I R H N I E D G S V Q L A  
 10 541/181 571/191  
 gac cac tac cag cag aac acc ccc atc ggc gac ggc ccc gtg ctg ctg ccc gac aac cac  
 D H Y Q Q N T P I G D G P V L L P D N H  
 601/201 631/211  
 tac ctg agc acc cag tcc gcc ctg agc aaa gac ccc aac gag aag cgc gat cac atg gtc  
 15 Y L S T Q S A L S K D P N E K R D H M V  
 661/221 691/231  
 ctg ctg gag ttc gtg acc gcc gcc ggg atc act ctc ggc atg gac gag ctg tac aag taa  
 L L E F V T A A G I T L G M D E L Y K \*

**List 2: Nucleic acid and amino acid sequence of F64L-E222G-GFP.**

20 1/1 31/11  
 atg gtg agc aag ggc gag gag ctg ttc acc ggg gtg gtg ccc atc ctg gtc gag ctg gac  
 M V S K G E E L F T G V V P I L V E L D  
 61/21 91/31  
 ggc gac gta aac ggc cac aag ttc agc gtg tcc ggc gag ggc gag ggc gat gcc acc tac  
 25 G D V N G H K F S V S G E G E G D A T Y  
 121/41 151/51  
 ggc aag ctg acc ctg aag ttc atc tgc acc acc ggc aag ctg ccc gtg ccc tgg ccc aca  
 G K L T L K F I C T T G K L P V P W P T  
 181/61 211/71  
 30 cta gtg acc acc ctg tct tac ggc gtg cag tgc ttc agc cgc tac ccc gac cac atg aag  
 L V T T L S Y G V Q C F S R Y P D H M K  
 241/81 271/91  
 cag cac gac ttc ttc aag tcc gcc atg ccc gaa ggc tac gtc cag gag cgc acc atc ttc  
 Q H D F F K S A M P E G Y V Q E R T I F  
 35 301/101 331/111  
 ttc aag gac gac ggc aac tac aag acc cgc gcc gag gtg aag ttc gag ggc gac acc ctg  
 F K D D G N Y K T R A E V K F E G D T L  
 361/121 391/131  
 gtg aac cgc atc gag ctg aag ggc atc gac ttc aag gag gac ggc aac atc ctg ggg cac  
 40 V N R I E L K G I D F K E D G N I L G H  
 421/141 451/151

```

aag ctg gag tac aac tac aac agc cac aac gtc tat atc atg gcc gac aag cag aag aac
K L E Y N Y N S H N V Y I M A D K Q K N
481/161 511/171
ggc atc aag gtg aac ttc aag atc cgc cac aac atc gag gac ggc agc gtg cag ctc gcc
5 G I K V N F K I R H N I E D G S V Q L A
541/181 571/191
gac cac tac cag cag aac acc ccc atc ggc gac ggc ccc gtg ctg ctg ccc gac aac cac
D H Y Q Q N T P I G D G P V L L P D N H
601/201 631/211
10 tac ctg agc acc cag tcc gcc ctg agc aaa gac ccc aac gag aag cgc gat cac atg gtc
Y L S T Q S A L S K D P N E K R D H M V
661/221 691/231
ctc cta ggg ttc gtg acc gcc gcc ggg atc act ctc ggc atg gac gag ctg tac aag taa
L L G F V T A A G I T L G M D E L Y K *

```

**15 List 3: Predicted nucleotide and amino acid sequence of coding region of GFP-F64L in PS350:**

```

1/1 31/11
ATG AGT AAA GGA GAA GAA CTT TTC ACT GGA GTT GTC CCA ATT CTT GTT GAA TTA GAT GGC
M S K G E E L F T G V V P I L V E L D G
20 61/21 91/31
GAT GTT AAT GGG CAA AAA TTC TCT GTT AGT GGA GAG GGT GAA GGT GAT GCA ACA TAC GGA
D V N G Q K F S V S G E G E G D A T Y G
121/41 151/51
AAA CTT ACC CTT AAA TTT ATT TGC ACT ACT GGG AAG CTA CCT GTT CCA TGG CCA ACG CTT
25 K L T L K F I C T T G K L P V P W P T L
181/61 211/71
GTC ACT ACT CTC TCT TAT GGT GTT CAA TGC TTT TCT AGA TAC CCA GAT CAT ATG AAA CAG
V T T L S Y G V Q C F S R Y P D H M K Q
241/81 271/91
30 CAT GAC TTT TTC AAG AGT GCC ATG CCC GAA GGT TAT GTA CAG GAA AGA ACT ATA TTT TAC
H D F F K S A M P E G Y V Q E R T I F Y
301/101 331/111
AAA GAT GAC GGG AAC TAC AAG ACA CGT GCT GAA GTC AAG TTT GAA GGT GAT ACC CTT GTT
K D D G N Y K T R A E V K F E G D T L V
35 361/121 391/131
AAT AGA ATC GAG TTA AAA GGT ATT GAT TTT AAA GAA GAT GGA AAC ATT CTT GGA CAC AAA
N R I E L K G I D F K E D G N I L G H K
421/141 451/151
ATG GAA TAC AAT TAT AAC TCA CAT AAT GTA TAC ATC ATG GCA GAC AAA CCA AAG AAT GGC
40 M E Y N Y N S H N V Y I M A D K P K N G

```



481/161 511/171  
ATC AAA GTT AAC TTC AAA ATT AGA CAC AAC ATT AAA GAT GGA AGC GTT CAA TTA GCA GAC  
I K V N F K I R H N I K D G S V Q L A D

541/181 571/191  
5 CAT TAT CAA CAA AAT ACT CCA ATT GGC GAT GGC CCT GTC CTT TTA CCA GAC AAC CAT TAC  
H Y Q Q N T P I G D G P V L L P D N H Y

601/201 631/211  
CTG TCC ACG CAA TCT GCC CTT TCC AAA GAT CCC AAC GAA AAG AGA GAT CAC ATG ATC CTT  
L S T Q S A L S K D P N E K R D H M I L

10 661/221 691/231  
CTT GAG TTT GTA ACA GCT GCT GGG ATT ACA CAT GGC ATG GAT GAA ggg tac aag taa  
L E F V T A A G I T H G M D E G Y K \*

## Legend to Figures

### Figure 1

This figure shows the absorption and emission spectrum of eF64L,E222G (PS699) and EGFP (PS279). eF64L,E222G has excitation peak at ca 470 nm and emission peak at ca 504 nm. EGFP has excitation peak at ca 490 nm and emission peak at ca 510 nm.

### Figure 2

This figure shows the images collected after Lipofectamine 2000 transfection. eF64L,E222G (PS699) is at the top of the right column referred to as E222G.

### Figure 3

10 Comparing the pH sensitivity of EGFP and eF64L,E222G.

## EXAMPLES

### *Example 1: Construction of GFP plasmid combining F64L and E222G and mammalian codon usage.*

Plasmids pEGFP-N1 (GenBank accession number U55762) and pEGFP-C1 (GenBank  
15 accession number U55763) both contain a derivative of GFP in which one extra amino acid has been added at position two to provide a better translational start sequence (a Kozak sequence) and so the total number of amino acids is increased by one to 239 instead of the 238 found in wildtype GFP. Therefore the denomination of mutations in GFP in these plasmids strictly should be referred to as e.g. F65L rather than F64L. However, to  
20 avoid this source of confusion and because the GFP community has adopted the numbering system of wildtype GFP in its communications, the numbers used here conform to the commonly used naming of mutations in wildtype GFP. The relevant mutations in this respect are F64L, S65T, and E222G.

Plasmids pEGFP-N1 and pEGFP-C1 contain the following mutations in the chromophore:  
25 F64L and S65T. The codon usage of the GFP DNA sequence has been optimized for expression in mammalian cells. N1 and C1 refer to the position of multiple cloning sites relative to the GFP sequence.

- To construct a plasmid combining F64L and E222G, pEGFP-N1 and pEGFP-C1 were first subjected to PCR with primers 9859 and 9860 described below. The primers are complementary to the DNA sequence around the chromophore region and introduce a point mutation changing the threonine at position 65 to serine. In addition the primers introduce a unique Spe1 restriction site by silent mutation. The 4.7 kb PCR products were digested with Spe1, religated, and transformed into E.coli. The resulting plasmids are referred to as PS399 (N1 context) and PS401 (C1 context). These plasmids contain the chromophore sequence 64-LSYG-67. Plasmids PS399 and PS401 were subjected to Quick-Change mutagenesis (Stratagene) employing PCR with primers 0225 and 0226 described below. These primers are complementary to sequences near the C-terminus of the GFP and change glutamate at position 222 to glycine, and in addition they introduce an Avr2 restriction site by silent mutation. The resulting plasmids are referred to as PS699 (N1 context) and PS701 (C1 context). They combine an LSYG chromophore with E222G with mammalian codon and is referred to as eF64L,E222G (see sequence list 2)
- 9859-top: 5'-TGTACTAGTGACCACCCTGTCTTACGGCGTGCA-3'  
 9860-bottom: 5'-CTGACTAGTGTGGGCCAGGGCACGGGCAGC-3'  
 0225-bottom: 5'-CCCGGGCGGCGGTCACGAACCCTAGGAGGACCATGTGATCGCG-3'  
 0226-top: 5'-CGCGATCACATGGTCCTCCTAGGGTTCGTGACCGCCGCCGGG-3'

### ***Example 2: Determination of spectral properties of proteins EGFP and***

#### ***eF64L,E222G.***

- Plasmids expressing EGFP from plasmid pEGFP-N1 (also referred to as PS279), and eF64L,E222G from plasmid PS699 were transfected into COS7 cells using lipofectamine 2000 (from Life Technologies) according to manufacturers recommendations. After 5 days cells were collected and resuspended in extraction buffer 50mM TRIS(pH8.0) with 1mM DTT. Cells were lysed by 3 cycles of freeze-thaw. Cell debris was centrifuged out at 10000g in a cooled centrifuge. NaCl was added to 100mM.

- Protein samples were analysed in an LS-50 luminometer (Perkin Elmer) in plastic cuvettes containing 500 microliter samples. Excitation spectra were obtained by collecting emission at 510 nm, with 10nm slits. Emission spectra were obtained by collecting emission with excitation set at 470nm, with 10 nm slits. The results are shown in Figure 1. eF64L,E222G has excitation peak at ca 470 nm and emission peak at ca 504 nm. EGFP has excitation peak at ca 490 nm and emission peak at ca 510 nm.

**Exempl 3: Determination of time to fluorescenc of EGFP and eF64L,E222G in CHO cells.**

Three, 2 well chambers with CHOIR cells were transfected with plasmid PS279 expressing EGFP and plasmid PS699 expression eF64L,E222G using the Lipofectamine  
5 transfection method.

Fluorescence from the cells was checked at regular intervals after transfection.

Lipofectamine 2000 transfection method was used to transfect EGFP and eF64L,E222G in one, 8-well chamber with CHOIR cells. Fluorescence from the cells was checked at regular intervals after transfection as described above. Images were taken from the same  
10 cell fields at each interval. Three different fields were observed for each plasmid. The microscope and camera settings were the same for each image. Optimal exposure time was taken from a chamber of cells with full EGFP expression (transfected 24 hours previously) to ensure the exposure does not saturate. The first images were taken from 45 minutes to 1 hour post transfection, thereafter with a 30-minute interval for the first 7.5 hours post  
15 transfection and an image was collected 26.5 hours post transfection. Five different fields were observed for each plasmid. Fluorescence was detected no later then 4 hours post transfection. Fluorescence in eF64L,E222G was detected in one field 2.5 hours post transfection. In the remaining fields, fluorescence was detected no later than 4 hours post transfection (Figure 2).

**20 Example 4: Comparing pH sensitivity over range pH 4.0 to pH 12.0 between EGFP and eF64L,E222G.**

Samples of semi-purified EGFP from PS279 and eF64L,E222G from PS699 proteins produced in COS7 cell expression are tested for pH sensitivity over a range from pH 4.0 to pH 12.5, with 0.5 point intervals. Excitation and emission scans were taken of each protein at the pH values of 4.0, 8.0, and 12.5. The results of the scans found EGFP's excitation max to be 490 nm and emission max to be 510 nm and eF64L,E222G 's excitation  
25 max to be 475 nm and emission max to be 504 nm. Different pH values did not affect the excitation or emission max. Single reads were made with excitation at 470 nm, emission at 510 nm and with 10 nm slits. The results show no clear differences between EGFP and  
30 eF64L,E222G regarding pH sensitivity, except what could be due to random fluctuation (Figure 3). This experiment has been repeated with essentially same result.

**Example 5: Construction of GFP plasmid combining F64L and E222G and jellyfish codon usage .**

A plasmid encoding a GFP directly derived from jellyfish with F64L (disclosed in figure 4 of WO97/11094,) was subjected to PCR with primers 9840 & 9841 described below. The  
5 PCR product was digested with restriction enzymes Age1 and Acc65 and ligated into pEGFP-N1 digested with Age1 and BsrG1. This replaces EGFP with F64L-GFP and introduces an amino acid change L236G near the c-terminus as a consequence of joining Acc65 and BsrG1 sites. This plasmid is referred to as PS350.

A plasmid encoding a GFP directly derived from jellyfish with F64L, S65T (disclosed in  
10 figure 5 of WO97/11094,) was subjected to PCR with primers 9840 & 9841 described below. The PCR product was digested with restriction enzymes Age1 and Acc65 and ligated into pEGFP-N1 digested with Age1 and BsrG1. This replaces EGFP with F64L, S65T-GFP and introduces an amino acid change L236G near the c-terminus as a consequence of joining Acc65 and BsrG1 sites. This plasmid is referred to as PS351.

15 Plasmid PS350 was subjected to QuickChange PCR (Stratagene) with primers 0317 & 0318 described below. This introduces E222G by mutation and an Avr2 restriction site by silent mutation. This plasmid is referred to as PS832.

Plasmid PS832 was subjected to QuickChange PCR (Stratagene) with primers 0325 & 0326 described below. This introduces L64F by mutation and a Psp1406 restriction site by  
20 silent mutation. This plasmid is referred to as PS845.

A plasmid encoding a GFP directly derived from jellyfish (disclosed in figure 2a of WO97/11094) was subjected to PCR with primers 9840 & 9841 described below. The PCR product was digested with restriction enzymes Age1 and Acc65 and ligated into pEGFP-N1 digested with Age1 and BsrG1. This replaces EGFP with wildtype GFP and  
25 introduces an amino acid change L236G near the c-terminus as a consequence of joining Acc65 and BsrG1 sites. This plasmid is referred to as PS854.

**Exempl 6: Construction f additional GFP plasmid combining F64L and E222G and mammalian codon usage.**

Plasmid PS399 was subjected to QuickChange PCR (Stratagen ) with primers 0327 & 0328 described below. This introduces L64F by mutation and a Psp1406 restriction site by  
5 silent mutation. This plasmid is referred to as PS844.

Plasmid PS699 was subjected to QuickChange PCR (Stratagene) with primers 0327 & 0328 described below. This introduces L64F by mutation and a Psp1406 restriction site by silent mutation. This plasmid is referred to as PS846.

- 9840-top: 5'-GTACCGGTCACCATGAGTAAAGGAGAAGAAC-3'
- 10 9841-bottom: 5'-TTATTGGTACCCTTCATCCATGCCATGTG-3'
- 0317-top: 5'-GAGATCACATGATCCTCCTAGGGTTTGTAACAGCTGCTGGG-3'
- 0318-bottom: 5'-CCCAGCAGCTGTTACAAACCCTAGGAGGATCATGTGATCTC-3'
- 0325-top: 5'-CCAACGCTTGTCACAACGTTTTCTTATGGTGTTTC-3'
- 0326-bottom: 5'-GAACACCATAAGAAAACGTTGTGACAAGCGTTGG-3'
- 15 0327-top: 5'-CCCACACTAGTGACAACGTTTTCTTACGGCGTG-3'
- 0328-bottom: 5'-GCACGCCGTAAGAAAACGTTGTCACTAGTGTGGG-3'

**Example 7: Comparison of relative brightness of GFPs in CHO cells.**

10 plasmids were constructed which combine some of the following features:

- F or L at position 64.
- 20 - S or T at position 65.
- E or G at position 222.
- "jellyfish" or "mammalian enhanced" GFP backbone.

The plasmids were transfected into CHO cells. One, two and four days later the cells were inspected visually in a fluorescence microscope by two people. The excitation was 475/40  
25 = blue light and the emission 510-560 = green light. Cells were scored on a "green" scale ranging from essentially black to extremely bright. Results did not change much with time. They are recorded in Table 1.

**Table 1**

Plasmid	"greenness"	GFP (* UVmax)	codon context	aa 64	aa 65	aa 222
PS854	black	jf-GFP *	jellyfish	F	S	E
PS845	almost black	jf-GFP-E222G	jellyfish	F	S	G
PS846	almost black	e-GFP-E222G	mammalian	F	S	G
PS844	almost black	e-GFP *	mammalian	F	S	E
PS350	light green	jf-GFP-F64L *	jellyfish	L	S	E
PS351	green	jf-GFP-S65T	jellyfish	L	T	E
PS832	green	jf-GFP-F64L,E222G	jellyfish	L	S	G
PS399	bright green	e-GFP-F64L *	mammalian	L	S	E
PS699	very bright green	e-GFP-F64L,E222G	mammalian	L	S	G
PS279	very bright green	EGFP	mammalian	L	T	E


## CLAIMS

1. A fluorescent protein derived from Green Fluorescent Protein (GFP) or any functional GFP analogue, wherein the amino acid in position 1 preceding the chromophore has been mutated and wherein the Glutamic acid in position 222 has been mutated said mutated
- 5 GFP has an excitation maximum at a higher wavelength and the fluorescence is increased when the mutated GFP is expressed in cells incubated at a temperature of 30°C or above compared to wild-type GFP.
2. A fluorescent protein according to the preceding claim, wherein the chromophore is in position 65-67 of the predicted primary amino acid sequence of GFP.
- 10 3. A fluorescent protein according to any one of the preceding claims, said protein being derived from *Aequoria victoria* or *Renilla reniformis*.
4. A fluorescent protein according to any one of the preceding claims, wherein the amino acid F in position 64 of the GFP has been substituted by an aliphatic amino acid.
5. A fluorescent protein according to any one of the preceding claims, wherein the amino
- 15 acid F in position 64 of the GFP has been substituted by an amino acid selected from the group consisting of L, I, V, A and G.
6. A fluorescent protein according to any one of the preceding claims, wherein the amino acid F in position 64 of the GFP has been substituted by L.
7. A fluorescent protein according to any one of the preceding claims, wherein the amino
- 20 acid E in position 222 of the GFP has been substituted by an amino acid selected from the group consisting of G, A, V, L, I, F, S, T, N, and Q.
8. A fluorescent protein according to any one of the preceding claims, wherein the amino acid E in position 222 of the GFP has been substituted by G.
9. A fluorescent protein according to any one of the preceding claims having the amino
- 25 acid sequence disclosed in sequence list 2.




10. A fusion compound consisting of a fluorescent protein (GFP) according to any of the preceding claims, wherein the GFP is linked to a polypeptide.
11. A fusion compound according to the preceding claim, wherein the polypeptide is a kinase, preferably the catalytic subunit of protein kinase A, or protein kinase C, or Erk1, or a  
5 cytoskeletal element.
12. A nucleotide sequence coding for the Fluorescent protein of any of the preceding claims.
13. A nucleotide sequence according to the preceding claim, shown in sequence list 2.
14. A nucleotide sequence according to any of the preceding claims in the form of a DNA  
10 sequence.
15. A host transformed with a DNA construct according to any of the preceding claims.
16. A process for preparing a polypeptide, comprising cultivating a host according to any of the preceding claims and obtaining therefrom the polypeptide expressed by said nucleotide sequence.
- 15 17. Use of the fluorescent protein according to any of the preceding claims in an *in vitro* assay for measuring protein kinase activity, or dephosphorylation activity, or for measuring protein redistribution.

Figure 1



**Figure 2**



Patent- og  
Varemærkestyrelse

10 MAJ 2001

Modtaget

Figure 3

Patent- og  
Varemærkestyrelsen

10 MAJ 2001

Modtaget

